Joseph Stringer
Stock Analyst at Needham
(3.70)
# 769
Out of 4,911 analysts
306
Total ratings
44.81%
Success rate
8.61%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Joseph Stringer
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GILD Gilead Sciences | Upgrades: Buy | $133 | $116.20 | +14.46% | 7 | Jul 25, 2025 | |
| RYTM Rhythm Pharmaceuticals | Maintains: Buy | $72 → $95 | $86.45 | +9.89% | 25 | Jul 9, 2025 | |
| STOK Stoke Therapeutics | Reiterates: Buy | $22 | $13.10 | +67.94% | 23 | Jul 1, 2025 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Buy | $320 → $377 | $328.81 | +14.66% | 22 | Jun 26, 2025 | |
| CDTX Cidara Therapeutics | Maintains: Buy | $36 → $54 | $61.85 | -12.69% | 13 | Jun 23, 2025 | |
| PHAT Phathom Pharmaceuticals | Maintains: Buy | $28 | $9.63 | +190.76% | 52 | Jun 6, 2025 | |
| VIR Vir Biotechnology | Reiterates: Buy | $14 | $5.65 | +147.79% | 18 | May 22, 2025 | |
| ANNX Annexon | Maintains: Buy | $16 → $11 | $2.51 | +338.25% | 19 | May 13, 2025 | |
| APLS Apellis Pharmaceuticals | Maintains: Buy | $40 → $29 | $19.59 | +48.03% | 20 | May 7, 2025 | |
| VRTX Vertex Pharmaceuticals | Reiterates: Hold | n/a | $469.65 | - | 6 | May 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $60 → $55 | $42.25 | +30.19% | 21 | Apr 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $60 | $36.27 | +65.43% | 17 | Apr 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $90 | $36.63 | +145.70% | 17 | Apr 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Hold | n/a | $1.10 | - | 13 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $10 | $1.57 | +536.94% | 17 | Mar 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Hold | n/a | $34.15 | - | 8 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $37 | $23.25 | +59.14% | 6 | Jan 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $32 → $18 | $11.03 | +63.19% | 2 | Aug 24, 2021 |
Gilead Sciences
Jul 25, 2025
Upgrades: Buy
Price Target: $133
Current: $116.20
Upside: +14.46%
Rhythm Pharmaceuticals
Jul 9, 2025
Maintains: Buy
Price Target: $72 → $95
Current: $86.45
Upside: +9.89%
Stoke Therapeutics
Jul 1, 2025
Reiterates: Buy
Price Target: $22
Current: $13.10
Upside: +67.94%
Alnylam Pharmaceuticals
Jun 26, 2025
Maintains: Buy
Price Target: $320 → $377
Current: $328.81
Upside: +14.66%
Cidara Therapeutics
Jun 23, 2025
Maintains: Buy
Price Target: $36 → $54
Current: $61.85
Upside: -12.69%
Phathom Pharmaceuticals
Jun 6, 2025
Maintains: Buy
Price Target: $28
Current: $9.63
Upside: +190.76%
Vir Biotechnology
May 22, 2025
Reiterates: Buy
Price Target: $14
Current: $5.65
Upside: +147.79%
Annexon
May 13, 2025
Maintains: Buy
Price Target: $16 → $11
Current: $2.51
Upside: +338.25%
Apellis Pharmaceuticals
May 7, 2025
Maintains: Buy
Price Target: $40 → $29
Current: $19.59
Upside: +48.03%
Vertex Pharmaceuticals
May 6, 2025
Reiterates: Hold
Price Target: n/a
Current: $469.65
Upside: -
Apr 30, 2025
Maintains: Buy
Price Target: $60 → $55
Current: $42.25
Upside: +30.19%
Apr 9, 2025
Reiterates: Buy
Price Target: $60
Current: $36.27
Upside: +65.43%
Apr 8, 2025
Reiterates: Buy
Price Target: $90
Current: $36.63
Upside: +145.70%
Mar 7, 2025
Reiterates: Hold
Price Target: n/a
Current: $1.10
Upside: -
Mar 4, 2025
Downgrades: Hold
Price Target: $10
Current: $1.57
Upside: +536.94%
Nov 8, 2024
Reiterates: Hold
Price Target: n/a
Current: $34.15
Upside: -
Jan 24, 2024
Upgrades: Buy
Price Target: $37
Current: $23.25
Upside: +59.14%
Aug 24, 2021
Maintains: Buy
Price Target: $32 → $18
Current: $11.03
Upside: +63.19%